In a race against time, Kris DeVault is seeking experimental treatment for his son, Brody, who was diagnosed with creatine transporter deficiency (CTD) shortly after birth. This rare genetic disorder impedes the brain and muscles from receiving the energy they need for proper development, causing significant delays in Brody’s speech and motor skills. Although there is currently no cure for CTD, a biotechnology firm in France, Ceres Brain Therapeutics, is in the process of developing a drug that may provide hope. However, this drug is still in its early stages and has not yet been approved for use in patients, leaving families like the DeVaults in a state of uncertainty.
The introduction of a new law in Montana is seen as a potential lifeline for families in similar situations. Previously, Montana’s
Source: Montana’s new “right to try” law can’t come soon enough for some via MIT Technology Review